Skip to main content

Advertisement

SpringerLink
Log in

Expression Status of Serine Protease 27: A Prognostic Marker for Esophageal Squamous Cell Carcinoma Treated with Preoperative Chemotherapy/Chemoradiotherapy

  • Translational Research
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

A previous study conducted a transcriptome analysis of paired normal and esophageal squamous cell carcinoma (ESCC) tissue samples. The results showed that the expression of serine protease 27 (PRSS27) was perturbed in tumor samples. Hence, this retrospective study aimed to validate the prognostic significance of PRSS27 in patients with preoperative treatment for ESCC.

Methods

We enrolled 86 patients who received preoperative treatment before esophagectomy for ESCC. The expression of PRSS27 in resected ESCC and biopsy tissue samples obtained before preoperative treatment was evaluated via immunostaining, and its relationship with clinicopathological features and prognosis was analyzed.

Results

In normal esophageal mucosa tissue samples, PRSS27 was expressed in the cytoplasm of spinous cells in the suprabasal layer and basal cells in the basal layer. Of 64 resected ESCC tissue samples, 35 (54.7%) expressed PRSS27 and 29 (45.3%) did not. Moreover, ectopic nuclear expression of PRSS27 was observed. Based on multivariate analysis, PRSS27 expression in resected tumor samples was a predictor of poor prognosis. In cases in which PRSS27 expression was observed in biopsy samples, patients with PRSS27-negative resected tumors had a better postoperative prognosis than those with PRSS27-positive resected tumors.

Conclusions

PRSS27 expression in resected ESCC tissue samples is a poor prognostic factor in ESCC patients with preoperative treatment. Furthermore, conversion of PRSS27 expression from positive in biopsy samples to negative in resected tumor samples is a predictor of good prognosis in these patients. Hence, PRSS27 status is an effective tool for decision making regarding adjuvant treatment in ESCC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Then EO, Lopez M, Saleem S, et al. Esophageal cancer: an updated surveillance epidemiology and end results database analysis. World J Oncol. 2020;11(2):55–64.

    Article  Google Scholar 

  2. Zhang M, Hu D, Wang S, et al. Clinicopathologic significance of HMGA2 expression’s correlation with prognosis of esophageal squamous cell carcinoma after Ivor Lewis esophagectomy. Minerva Chir. 2016;71(4):239–44.

    PubMed  Google Scholar 

  3. Shi M, Wang Z, Song L, et al. Low expression of claudin-4: an indicator of recurrence in esophageal squamous cell carcinoma after Ivor Lewis esophagectomy? Med Oncol. 2014;31(5):951.

    Article  Google Scholar 

  4. Natsugoe S, Okumura H, Matsumoto M, et al. The role of salvage surgery for recurrence of esophageal squamous cell cancer. Eur J Surg Oncol. 2006;32(5):544–7.

    Article  CAS  Google Scholar 

  5. Miyata H, Sugimura K, Motoori M, et al. Clinical implications of conversion surgery after induction therapy for T4b thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 2019;26(13):4737–43.

    Article  Google Scholar 

  6. Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan, 2012. Esophagus. 2019;16(3):221–45.

    Article  Google Scholar 

  7. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.

    Article  Google Scholar 

  8. Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.

    Article  Google Scholar 

  9. Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68–74.

    Article  Google Scholar 

  10. Otsubo T, Yamada K, Hagiwara T, et al. DNA hypermethyation and silencing of PITX1 correlated with advanced stage and poor postoperative prognosis of esophageal squamous cell carcinoma. Oncotarget. 2017;8(48):84434–48.

    Article  Google Scholar 

  11. Li W, Danilenko DM, Bunting S, et al. The serine protease marapsin is expressed in stratified squamous epithelia and is up-regulated in the hyperproliferative epidermis of psoriasis and regenerating wounds. J Biol Chem. 2009;284(1):218–28.

    Article  CAS  Google Scholar 

  12. Raman K, Trivedi NN, Raymond WW, et al. Mutational tail loss is an evolutionary mechanism for liberating marapsins and other type I serine proteases from transmembrane anchors. J Biol Chem. 2013;288(15):10588–98.

    Article  CAS  Google Scholar 

  13. Sobin LH, Gospodarowicz MK, Wittekind C. The Union for International Cancer Control (UICC) TNM classification of malignant tumors. 7th edn. Hoboken: Wiley; 2011.

    Google Scholar 

  14. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.

    Article  CAS  Google Scholar 

  15. Japan Esophageal Society. Japanese classification of esophageal cancer, 11th Edition: part II and III. Esophagus. 2017;14(1):37–65.

    Article  Google Scholar 

  16. Zhou J, Li W, Jin T, et al. Gene microarray analysis of lncRNA and mRNA expression profiles in patients with hypopharyngeal squamous cell carcinoma. Int J Clin Exp Med. 2015;8(4):4862–82.

    PubMed  PubMed Central  Google Scholar 

  17. Zhang J, Lin H, Jiang H, et al. A key genomic signature associated with lymphovascular invasion in head and neck squamous cell carcinoma. BMC Cancer. 2020;20(1):266.

    Article  CAS  Google Scholar 

  18. Jiang S, Zhang Q, Su Y, et al. Network-based differential analysis to identify molecular features of tumorigenesis for esophageal squamous carcinoma. Molecules. 2018;23(1):88.

    Article  Google Scholar 

  19. Chen Y, Liao LD, Wu ZY, et al. Identification of key genes by integrating DNA methylation and next-generation transcriptome sequencing for esophageal squamous cell carcinoma. Aging (Albany NY). 2020;12(2):1332–65.

    Article  CAS  Google Scholar 

  20. Suzuki T, Yajima S, Ishioka N, et al. Prognostic significance of high serum p53 antibody titers in patients with esophageal squamous cell carcinoma. Esophagus. 2018;15(4):294–300.

    Article  Google Scholar 

Download references

Acknowledgments

The authors thank Drs. Miwa Tamura-Nakano and Chinatsu Oyama in the NCGM EM Support Unit for their technical support in the histological analysis, and Ms. Yasuko Nozaki for her technical assistance. They would also like to thank Enago (www.enago.jp) for the English-language review. This work was supported by JSPS KAKENHI grant numbers JP15K10124, JP19K08457, and by grants from the NCGM (26-117, 29-1019 and 20A1017).

Author information

Authors and Affiliations

  1. Department of Surgery, National Center for Global Health and Medicine, Tokyo, Japan

    Atsuko Kataoka MD, Kazuhiko Yamada MD, PhD, Masayoshi Terayama MD, Takayuki Sugimoto MD & Kyoko Nohara MD, PhD

  2. Department of Gastroenterology, The Research Center for Hepatitis and Immunology, Research Institute, National Center for Global Health and Medicine, Chiba, Japan

    Atsuko Kataoka MD, Teruki Hagiwara MS, Masayoshi Terayama MD & Yuki I. Kawamura PhD

  3. Course of Advanced and Specialized Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan

    Atsuko Kataoka MD, Kazuhiko Yamada MD, PhD & Masayoshi Terayama MD

  4. Pathology Division of Clinical Laboratory, National Center for Global Health and Medicine, Tokyo, Japan

    Toru Igari MD, PhD

  5. Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Tokyo, Japan

    Chizu Yokoi MD, PhD

Authors
  1. Atsuko Kataoka MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuhiko Yamada MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Teruki Hagiwara MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masayoshi Terayama MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takayuki Sugimoto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kyoko Nohara MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Toru Igari MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chizu Yokoi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yuki I. Kawamura PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuki I. Kawamura PhD.

Ethics declarations

Disclosures

Atsuko Kataoka, Kazuhiko Yamada, Teruki Hagiwara, Masayoshi Terayama, Takayuki Sugimoto, Kyoko Nohara, Toru Igari, Chizu Yokoi, and Yuki I. Kawamura have no financial or other relationships that could lead to a commercial interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kataoka, A., Yamada, K., Hagiwara, T. et al. Expression Status of Serine Protease 27: A Prognostic Marker for Esophageal Squamous Cell Carcinoma Treated with Preoperative Chemotherapy/Chemoradiotherapy. Ann Surg Oncol 28, 5373–5381 (2021). https://doi.org/10.1245/s10434-020-09550-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-020-09550-y

Search

Navigation